Developed as an original domestic technology, MiraJet is the first commercially available laser-guided needleless drug delivery device, introduced in 2020.
The Korean Dermatological Association (KDA) successfully opened the international academic conference "Korea Derma 2023" today (23rd) at The K-Hotel in Seoul.
This year's Korea Derma is being held in person with full participation, featuring a total of 50 sessions covering anti-aging and various skin disorders, consisting of 200 lectures over two days (23rd-24th).
After the conclusion of all lectures on the first day, a satellite session was held, providing an opportunity for accessible communication between participating companies and experts.
JSK Biomed arranged a space to introduce the innovative technology of their needleless syringe, MiraJet, and continued to communicate with experts at the venue until late.
The chairperson for this session was Director Ko Woo-Seok from GOS Skin Clinic, Director Seo Seok-bae from Seo-Ah Song Dermatology Clinic, and Director Park Jun-hong from Ohwol's Morning Dermatology Clinic took the stage as speakers. They provided detailed explanations of the innovative technology of MiraJet, as well as its effectiveness and safety, based on actual clinical experiences.
MiraJet is the world's first laser-based drug delivery system developed by JSK Biomed, utilizing intense energy from the Er: YAG laser to instantly penetrate medication into the skin without using traditional syringe needles.
What sets MiraJet apart is its ability to uniformly deliver small amounts of medication to the skin, proving its effectiveness and safety in a wide range of skin care procedures such as acne scar treatment, wrinkle reduction, pigmentation correction, and anti-aging. It revitalizes the clinical field by boosting energy with its proven efficacy and safety.
SK Biomed CEO Jeon Jin-woo stated, "It is even more meaningful to present MiraJet, developed with our country's original technology, in a gathering where dermatologists worldwide come together. We have once again confirmed the medical community's strong interest and response to the innovative nature of MiraJet, and we aspire to leap towards a broader global market, assisting in clinical fields and patients."
